GO:1903180 negative regulation of dopamine biosynthetic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903180 describes any process that stops, prevents, or reduces the frequency, rate, or extent of dopamine biosynthetic process.
• Dopamine biosynthesis is tightly controlled because dopamine modulates reward, motor control, cognition, and immune responses.
• Negative regulation occurs via feedback inhibition of tyrosine hydroxylase, transcriptional repression, and microRNA-mediated silencing.
• Dysregulation of this process is implicated in schizophrenia, addiction, obesity, and inflammatory diseases.
• Key genes include TH, DDC, SLC6A3, DRD2, and miR-133b, which serve as targets for CRISPR knockout, knock-in, and overexpression models.
• Studying GO:1903180 requires integrated approaches such as RNA-seq, proteomics, and CRISPR screening to dissect regulatory networks.
Description
Dopamine is a catecholamine neurotransmitter essential for motor control, reward processing, and emotional regulation. Its biosynthesis proceeds from tyrosine to L-DOPA and then to dopamine, catalyzed by tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (DDC). The term GO:1903180, negative regulation of dopamine biosynthetic process, encompasses any mechanism that reduces the production of dopamine. This regulation is critical because excessive dopamine signaling is associated with psychosis and addiction, while deficient dopamine contributes to Parkinsonism and depression. Understanding the negative regulators of dopamine synthesis provides insight into homeostatic control and offers therapeutic targets for neuropsychiatric disorders. Recent studies have also linked dopamine biosynthesis to immune modulation, highlighting its broader physiological significance.
negative regulation of dopamine biosynthetic process At A Glance
| GO ID | GO:1903180 |
|---|---|
| GO term | negative regulation of dopamine biosynthetic process |
| Ontology | biological_process |
| Synonym | inhibition of dopamine biosynthesis; downregulation of dopamine synthesis; negative regulation of dopamine formation |
| Major function | Reduces the rate of dopamine production by inhibiting enzymes, repressing gene expression, or promoting degradation of biosynthetic components. |
| Related processes | dopamine biosynthetic process (GO:0042416); regulation of dopamine biosynthetic process (GO:1903179); negative regulation of dopamine metabolic process (GO:1903181) |
| Key enzymes | Tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (DDC) |
| Key regulators | D2 autoreceptors, microRNAs (e.g., miR-133b), transcription factors (e.g., Nurr1) |
| Disease relevance | Schizophrenia, addiction, obesity, Parkinson's disease, inflammatory disorders |
What Is GO:1903180?
GO:1903180 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of dopamine biosynthetic process. It includes mechanisms such as feedback inhibition of biosynthetic enzymes, transcriptional repression of genes encoding these enzymes, and degradation of their mRNAs or proteins. This term is a child of negative regulation of dopamine metabolic process and negative regulation of catecholamine biosynthetic process.
Why Is negative regulation of dopamine biosynthetic process Important in Cell Biology?
Negative regulation of dopamine biosynthesis is essential for maintaining optimal dopamine levels, as both excess and deficiency lead to pathological states. Dysregulated dopamine synthesis is a core feature of schizophrenia, where cortical excitation-inhibition imbalance and dopaminergic hyperactivity contribute to psychosis. In addiction, stress-induced alterations in the dopaminergic reward system involve changes in dopamine biosynthesis and its regulation. Furthermore, dopamine negatively regulates systemic inflammation through NLRP3 inflammasome inhibition, and its biosynthesis must be tightly controlled to avoid immune dysregulation. Thus, understanding GO:1903180 is crucial for developing targeted therapies for neuropsychiatric and inflammatory diseases.
• Maintains dopamine homeostasis to prevent neurotoxicity from excess dopamine.
• Modulates reward circuitry and stress responses, impacting addiction vulnerability.
• Regulates immune cell function, including NLRP3 inflammasome and group 2 innate lymphoid cells.
• Influences attention and cognitive processes, as shown by gut microbial modulation of dopaminergic signalling.
• Contributes to prosocial and parenting behaviours via shared neural substrates.
• Involved in negative feedback regulation of alcohol ingestion through FGF21-PVH oxytocin-VTA dopamine system.
• Dysregulation is linked to schizophrenia and psychosis through hippocampal circuit dysfunction.
• Provides targets for CRISPR-based gene editing to study and treat dopamine-related disorders.
What Happens During negative regulation of dopamine biosynthetic process?
Feedback inhibition of tyrosine hydroxylase
In simple terms: When dopamine levels get too high, the enzyme that makes dopamine is switched off.
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis. Dopamine itself can inhibit TH activity through end-product feedback inhibition, binding to the enzyme and reducing its catalytic rate. This feedback loop is mediated by D2 autoreceptors, which upon dopamine binding activate Gi/o proteins that inhibit adenylyl cyclase, lowering cAMP and PKA activity, thereby reducing TH phosphorylation and activity. This mechanism rapidly adjusts dopamine synthesis to match demand.
Transcriptional repression of dopamine biosynthetic genes
In simple terms: The cell can make fewer dopamine-making enzymes by turning down the genes that code for them.
Long-term negative regulation involves reduced transcription of TH and DDC genes. Transcription factors such as Nurr1 (NR4A2) are essential for TH expression; however, repressors like the orphan nuclear receptor SHP (NR0B2) can inhibit Nurr1-mediated transactivation. Additionally, the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) regulate dopamine storage and reuptake, indirectly affecting synthesis through feedback. Epigenetic modifications, including DNA methylation and histone deacetylation, also silence these genes under certain conditions.
MicroRNA-mediated silencing
In simple terms: Small RNA molecules can block the production of dopamine-making proteins.
MicroRNAs (miRNAs) such as miR-133b and miR-7 negatively regulate dopamine biosynthesis by binding to the 3' untranslated region of mRNAs encoding TH, DDC, or other components, leading to translational repression or mRNA degradation. For example, miR-133b is downregulated in Parkinson's disease, leading to increased TH expression, which may contribute to disease pathology. This layer of regulation allows fine-tuning of dopamine synthesis in response to cellular signals.
Protein degradation and post-translational modifications
In simple terms: The enzymes that make dopamine can be tagged for destruction or modified to work less efficiently.
Post-translational modifications of TH, such as phosphorylation at Ser40, activate the enzyme, while dephosphorylation reduces activity. Ubiquitination and proteasomal degradation of TH can also occur under conditions of oxidative stress or prolonged dopamine excess. These modifications provide rapid and reversible control of dopamine biosynthesis.
Key Genes Involved in GO:1903180 negative regulation of dopamine biosynthetic process
The following genes and proteins are central to the negative regulation of dopamine biosynthetic process, based on their established roles in dopamine synthesis, feedback inhibition, and regulatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TH | Rate-limiting enzyme in dopamine biosynthesis; subject to feedback inhibition | Target for knockout and point mutation to study dopamine regulation |
| DDC | Converts L-DOPA to dopamine; regulated by miRNAs | Knockout models to assess dopamine synthesis and behavior |
| SLC6A3 (DAT) | Dopamine transporter; regulates reuptake and feedback | Knockout and knock-in models for addiction and ADHD research |
| DRD2 | Dopamine D2 receptor; mediates autoreceptor feedback inhibition | Point mutation and knockout to study autoreceptor function |
| NR4A2 (Nurr1) | Transcription factor essential for TH expression | Overexpression and knockout to study transcriptional regulation |
| NR0B2 (SHP) | Orphan nuclear receptor; represses Nurr1-mediated TH transcription | Knockout to investigate negative regulation |
| miR-133b | MicroRNA that silences TH and other dopaminergic genes | Overexpression and knockout to study miRNA-mediated silencing |
| miR-7 | MicroRNA that targets dopamine biosynthetic genes | Knockout and overexpression models |
| COMT | Enzyme that degrades dopamine; indirectly affects synthesis | Knockout models for dopamine turnover |
| MAO-A/B | Monoamine oxidases that degrade dopamine | Knockout and point mutation to study degradation |
| VMAT2 (SLC18A2) | Vesicular monoamine transporter; packages dopamine into vesicles | Knockout to study storage and feedback |
| FGF21 | Hormone involved in negative feedback regulation of alcohol ingestion via dopamine system | Knockout and overexpression models |
| Oxytocin | Neuropeptide that modulates VTA dopamine system | Knockout and knock-in models |
| NLRP3 | Inflammasome inhibited by dopamine; links dopamine to inflammation | Knockout models to study immune-dopamine crosstalk |
| ILC2 | Group 2 innate lymphoid cells; dopamine inhibits their function | Knockout and overexpression models |
| 3-HAA | Gut microbial metabolite that modulates dopaminergic signalling | Metabolite supplementation and gene editing |
| BDNF | Neurotrophic factor that influences dopaminergic neuron survival and function | Knockout and overexpression models |
| COMT | Catechol-O-methyltransferase; degrades dopamine | Knockout models for dopamine regulation |
How Is negative regulation of dopamine biosynthetic process Regulated?
The negative regulation of dopamine biosynthetic process is controlled at multiple levels. Short-term feedback inhibition of TH by dopamine via D2 autoreceptors rapidly reduces enzyme activity. Long-term regulation involves transcriptional repression of TH and DDC by factors such as SHP and miRNAs like miR-133b. Additionally, stress and hormonal signals, including FGF21, can modulate dopamine synthesis through feedback circuits involving oxytocin and the VTA. Gut microbial metabolites, such as 3-hydroxyanthranilic acid, also influence dopaminergic signalling and attention. These regulatory mechanisms ensure dopamine levels are maintained within a narrow physiological range.
negative regulation of dopamine biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TH | Parkinson's disease, schizophrenia | Knockout and point mutation in dopaminergic neurons |
| DRD2 | Schizophrenia, addiction | Knockout and knock-in mice to study autoreceptor feedback |
| FGF21 | Alcohol use disorder | Overexpression and knockout models |
| NLRP3 | Inflammatory diseases | Knockout mice to study dopamine-NLRP3 crosstalk |
| miR-133b | Parkinson's disease | Overexpression and knockout in cell models |
Schizophrenia and Psychosis
Dopaminergic hyperactivity is a hallmark of schizophrenia, and negative regulation of dopamine biosynthesis is impaired in this disorder. Cortical excitation-inhibition imbalance and hippocampal circuit dysfunction contribute to psychosis by disrupting dopamine homeostasis. Genetic variants in genes regulating dopamine synthesis, such as DRD2 and COMT, have been associated with schizophrenia risk. Understanding GO:1903180 may reveal new therapeutic targets for normalizing dopamine levels.
Addiction and Reward Disorders
Stress alters the dopaminergic reward system, and negative feedback regulation of dopamine biosynthesis is critical for preventing excessive dopamine release during alcohol or drug consumption. The FGF21-PVH oxytocin-VTA dopamine system mediates negative feedback regulation of alcohol ingestion, highlighting the role of GO:1903180 in addiction. Dysregulation of this process can lead to compulsive behaviors and substance use disorders.
Obesity and Metabolic Disorders
Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity, suggesting that negative regulation of dopamine biosynthesis is linked to metabolic and cognitive dysfunction. Dopamine also regulates systemic inflammation through NLRP3 inflammasome inhibition, and its biosynthesis must be tightly controlled to prevent inflammatory diseases.
From negative regulation of dopamine biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TH feedback inhibition regulate dopamine synthesis? | Point mutation of TH phosphorylation sites (e.g., Ser40) via CRISPR |
| What is the role of D2 autoreceptors in negative regulation? | Knockout of DRD2 in dopaminergic neurons |
| How does miR-133b affect dopamine biosynthesis? | Overexpression and knockout of miR-133b in SH-SY5Y cells |
| Does FGF21 negatively regulate alcohol ingestion via dopamine? | Knockout and overexpression of FGF21 in mice |
| What is the impact of gut microbial metabolites on dopaminergic signalling? | Metabolite supplementation and CRISPR knockout of target genes |
| How does dopamine inhibit NLRP3 inflammasome? | Knockout of NLRP3 in macrophages treated with dopamine |
How to Study the negative regulation of dopamine biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify transcriptional repression of TH/DDC |
| Proteomics | Protein abundance and modifications | Assess TH phosphorylation and degradation |
| CRISPR knockout screen | Loss-of-function effects on dopamine levels | Discover novel negative regulators |
| CRISPR activation screen | Gain-of-function effects | Identify genes whose overexpression reduces dopamine |
| Fast-scan cyclic voltammetry | Real-time dopamine release | Measure feedback inhibition in vivo |
| Microdialysis | Extracellular dopamine concentrations | Monitor dopamine dynamics in animal models |
| Fluorescent biosensors | Intracellular dopamine levels | Live-cell imaging of dopamine regulation |
| Western blot | Protein expression and phosphorylation | Validate TH inhibition |
Transcriptomic Analysis
RNA-seq can quantify expression of dopamine biosynthetic genes (TH, DDC) and regulatory miRNAs under conditions that induce negative regulation. This method identifies transcriptional changes and alternative splicing events.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics measures protein levels and post-translational modifications of TH and DDC, revealing feedback inhibition through phosphorylation changes.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of dopamine biosynthesis. Libraries targeting kinases, phosphatases, and transcription factors are particularly useful.
Imaging and Neurochemical Assays
Fast-scan cyclic voltammetry and microdialysis measure real-time dopamine release in vivo, while fluorescent biosensors (e.g., dLight) enable spatial and temporal resolution of dopamine dynamics.
How CRISPR Can Be Used to Study GO:1903180 negative regulation of dopamine biosynthetic process
Knockout
CRISPR knockout of genes such as TH, DDC, or DRD2 can abolish dopamine biosynthesis or its feedback inhibition, providing causal evidence for their roles in GO:1903180. Knockout models are essential for studying the consequences of losing negative regulation.
Point Mutation
Introducing point mutations in TH (e.g., Ser40Ala) or DRD2 can dissect specific phosphorylation or ligand-binding sites involved in negative regulation. This approach reveals mechanistic details without completely eliminating gene function.
Knock-in
Knock-in of tagged versions of TH or DDC (e.g., GFP or HA tags) allows real-time tracking of protein localization and turnover, facilitating studies of negative regulation under physiological conditions.
Overexpression
Overexpression of negative regulators such as miR-133b, SHP, or FGF21 can suppress dopamine biosynthesis, mimicking pathological states. This is useful for validating targets and testing therapeutic interventions.
How EDITGENE Supports negative regulation of dopamine biosynthetic process Research
Researchers studying negative regulation of dopamine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in dopamine homeostasis or merely correlated with it. EDITGENE provides comprehensive CRISPR gene editing services to enable precise functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of dopamine biosynthetic process research.
Frequently Asked Questions About negative regulation of dopamine biosynthetic process
What is GO:1903180?
GO:1903180 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of dopamine biosynthetic process.
What genes are involved in negative regulation of dopamine biosynthetic process?
Key genes include TH, DDC, DRD2, SLC6A3, NR4A2, NR0B2, miR-133b, and FGF21.
How is dopamine biosynthesis negatively regulated?
Through feedback inhibition of tyrosine hydroxylase, transcriptional repression, miRNA-mediated silencing, and protein degradation.
What diseases are associated with dysregulation of this process?
Schizophrenia, addiction, obesity, Parkinson's disease, and inflammatory disorders.
What is the role of D2 autoreceptors in dopamine regulation?
D2 autoreceptors mediate feedback inhibition of dopamine synthesis and release by reducing cAMP and PKA activity.
How can CRISPR be used to study negative regulation of dopamine biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models can dissect gene function and regulatory mechanisms.
What methods are used to measure dopamine biosynthesis?
RNA-seq, proteomics, fast-scan cyclic voltammetry, microdialysis, and fluorescent biosensors.
Is dopamine involved in immune regulation?
Yes, dopamine inhibits NLRP3 inflammasome and group 2 innate lymphoid cell-driven inflammation.
What is the link between gut microbiota and dopamine biosynthesis?
Gut microbial metabolite 3-hydroxyanthranilic acid modulates dopaminergic signalling and attention in obesity.
How does stress affect dopamine biosynthesis?
Stress alters the dopaminergic reward system and can dysregulate negative feedback mechanisms.
Conclusion
GO:1903180, negative regulation of dopamine biosynthetic process, is a critical biological process that maintains dopamine homeostasis and prevents neuropsychiatric and inflammatory disorders. Understanding its molecular mechanisms, key genes, and regulatory pathways provides a foundation for developing targeted therapies. EDITGENE's CRISPR services empower researchers to dissect these pathways with precision and accelerate discoveries in dopamine-related diseases.
References
- 1. Howes OD et al.. 2022. Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance.. Biol Psychiatry 92(6):501-513 PMID: 36008036
- 2. Baik JH. 2020. Stress and the dopaminergic reward system.. Exp Mol Med 52(12):1879-1890 PMID: 33257725
- 3. Yan Y et al.. 2015. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome.. Cell 160(1-2):62-73 PMID: 25594175
- 4. Cao Y et al.. 2023. Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity.. Immunity 56(2):320-335.e9 PMID: 36693372
- 5. Castells-Nobau A et al.. 2026. Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity.. Gut 75(4):705-724 PMID: 41015495
- 6. Sun F et al.. 2026. Shared neural substrates of prosocial and parenting behaviours.. Nature 654(8118):454-464 PMID: 41781625
- 7. Matsui S et al.. 2026. Negative feedback regulation of alcohol ingestion through the FGF21-PVH oxytocin-VTA dopamine system.. Proc Natl Acad Sci U S A 123(3):e2525172122 PMID: 41533444
- 8. Knight S et al.. 2022. Hippocampal circuit dysfunction in psychosis.. Transl Psychiatry 12(1):344 PMID: 36008395
